Paper17517854
Rosiglitazone and cardiovascular risk.
Psaty BM and 1 other. N Engl J Med, 2007. Cited by 123 papers, by iCite.
Cite this record
ConductScience Library. Rosiglitazone and cardiovascular risk. Papers, record 17517854. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17517854
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiovascular Diseases | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Drug Approval | Major topic |
| Hypoglycemic Agents | Major topic |
| Myocardial Infarction | Major topic |
| Thiazolidinediones | Major topic |
| Adverse Drug Reaction Reporting Systems | |
| Clinical Trials, Phase IV as Topic | |
| Humans | |
| Meta-Analysis as Topic | |
| Randomized Controlled Trials as Topic | |
| Risk Assessment | |
| Rosiglitazone | |
| United States | |
| United States Food and Drug Administration |
Source PubMed
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 17551160 | Rosiglitazone--continued uncertainty about safety. | https://conductscience.org/library/papers/17551160 | PubMed |
| Comment in | 17551161 | Rosiglitazone and cardiotoxicity--weighing the evidence. | https://conductscience.org/library/papers/17551161 | PubMed |
| Comment in | 17806134 | Rosiglitazone and cardiovascular risk. | https://conductscience.org/library/papers/17806134 | PubMed |
| Comment on | 17517853 | Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. | https://conductscience.org/library/papers/17517853 | PubMed |
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41008970 | Elucidating Key Components and Mechanisms Underlying the Synergistic Anti-Type 2 Diabetes Effect of Morus alba L. and Siraitia grosvenorii Combination: An Integrated In Vitro Enzymology, Untargeted Metabolomics, and Network Pharmacology Approach. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/41008970 | PubMed |
| 38803898 | Chronotherapy involving rosiglitazone regulates the phenotypic switch of vascular smooth muscle cells by shifting the phase of TNF-α rhythm through triglyceride accumulation in macrophages. | Heliyon | 2024 | https://conductscience.org/library/papers/38803898 | PubMed |
| 38683294 | The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. | Adv Ther | 2024 | https://conductscience.org/library/papers/38683294 | PubMed |
| 37514148 | Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37514148 | PubMed |
| 37508471 | Exploring Rosiglitazone's Potential to Treat Alzheimer's Disease through the Modulation of Brain-Derived Neurotrophic Factor. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/37508471 | PubMed |
| 36793276 | Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/36793276 | PubMed |
| 33623531 | Alismatis Rhizoma Triterpenes Alleviate High-Fat Diet-Induced Insulin Resistance in Skeletal Muscle of Mice. | Evid Based Complement Alternat Med | 2021 | https://conductscience.org/library/papers/33623531 | PubMed |
| 33116714 | Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity. | Diabetes Metab Syndr Obes | 2020 | https://conductscience.org/library/papers/33116714 | PubMed |
| 32855239 | Induction of UCP1 and thermogenesis by a small molecule via AKAP1/PKA modulation. | J Biol Chem | 2020 | https://conductscience.org/library/papers/32855239 | PubMed |
| 32024657 | Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. | BMJ | 2020 | https://conductscience.org/library/papers/32024657 | PubMed |
| 31885827 | Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes. | Oxid Med Cell Longev | 2019 | https://conductscience.org/library/papers/31885827 | PubMed |
| 27330371 | Drug safety: The concept, inception and its importance in patients' health. | Saudi Pharm J | 2016 | https://conductscience.org/library/papers/27330371 | PubMed |
| 26978569 | Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert. | Med Care | 2016 | https://conductscience.org/library/papers/26978569 | PubMed |
| 25826194 | Against vaccine assay secrecy. | Hum Vaccin Immunother | 2015 | https://conductscience.org/library/papers/25826194 | PubMed |
| 24897284 | Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes. | Pharmacogenomics | 2014 | https://conductscience.org/library/papers/24897284 | PubMed |
| 24563375 | Systematic reviews to ascertain the safety of diabetes medications. | Curr Diab Rep | 2014 | https://conductscience.org/library/papers/24563375 | PubMed |
| 24068766 | Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010. | BMJ Open | 2013 | https://conductscience.org/library/papers/24068766 | PubMed |
| 23738041 | Site-specific antioxidative therapy for prevention of atherosclerosis and cardiovascular disease. | Oxid Med Cell Longev | 2013 | https://conductscience.org/library/papers/23738041 | PubMed |
| 23695817 | Interpreting adverse signals in diabetes drug development programs. | Diabetes Care | 2013 | https://conductscience.org/library/papers/23695817 | PubMed |
| 23564465 | Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m(2): A Surgeon's Perspective. | Obes Surg | 2013 | https://conductscience.org/library/papers/23564465 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17517854
GET https://conductscience.org/api/papers/v1/17517854/cited_by?page=2